Ibuprofen does not worsen COVID-19 symptoms: study | Inquirer News

Ibuprofen does not worsen COVID-19 symptoms: study

/ 08:48 AM May 08, 2021
Picture taken 10 June 2005 in Paris of commonly used painkillers medecines based on Ibuprofen, an anti-inflammatory drug. According to a study, Ibuprofen would increased the risk of heart attack by almost a quarter.   AFP PHOTO JACK GUEZ (Photo by JACK GUEZ / AFP)

(AFP / file photo)

PARIS – Taking anti-inflammatory drugs like ibuprofen does not increase the risk of developing a severe form of COVID-19 or of dying from it, according to a new study, the largest so far on this class of medicines.

At the start of the coronavirus pandemic there was concern over the potential effects of non-steroidal anti-inflammatory drugs (NSAIDs), which are used to treat everything from minor pain to chronic arthritis and cardiovascular disease.


But observational research published Saturday in the medical journal Lancet Rheumatology, based on 72,000 hospitalised patients, found that the drugs “do not increase the mortality or severity” of COVID-19.

The authors recommended that doctors should continue to prescribe NSAIDs as they have in the past.


“When the pandemic began over a year ago, we needed to be sure that these common medications would not lead to worse outcomes in people with COVID-19,” lead author Ewen Harrison, a professor at the University of Edinburgh, said in a press release.

“We now have clear evidence that NSAIDs are safe to use in patients with COVID-19, which should provide reassurance to both clinicians and patients that they can continue to be used in the same way as before the pandemic began.”

The NSAID family of anti-inflammatory drugs includes those widely used by the general public like ibuprofen — an active substance in common drugs, such as Nurofen or Advil — or ketoprofen.

Death rates the same

Concerns over the drugs emerged at the start of the Covid pandemic and centred on suspicions that they can worsen infections, especially bacterial.

In March 2020, for example, the World Health Organization (WHO) recommended that people suffering COVID-19 symptoms avoid self-medicating with ibuprofen, after French officials warned that anti-inflammatory drugs could worsen effects of the virus.

The new research examined data on 72,000 Covid patients admitted to 255 health centres in England, Scotland and Wales between January and August 2020.

Of these, 4,211 had taken NSAIDs before hospitalisation.


The study found that the proportion of death was similar regardless of whether patients had taken the drugs or not — 30.4 percent for those who had and 31.3 percent for those who had not.

It also found that those who took NSAIDs were “no more likely to be admitted to critical care, need invasive or non-invasive ventilation, or require oxygen”.

There were some limitations to the research, however, including that in the UK ibuprofen is the most commonly used NSAID, so it is unclear whether the results could be as applicable to other countries where different NSAIDs are used.

They also did not know how long patients had taken the drugs and whether they were taking them for a serious chronic condition or temporary symptoms.


For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: COVID-19, Drugs, ibuprofen
For feedback, complaints, or inquiries, contact us.

© Copyright 1997-2021 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.